首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   877752篇
  免费   72947篇
  国内免费   2389篇
耳鼻咽喉   12955篇
儿科学   24885篇
妇产科学   25607篇
基础医学   126390篇
口腔科学   25855篇
临床医学   77183篇
内科学   167910篇
皮肤病学   17180篇
神经病学   71109篇
特种医学   35609篇
外国民族医学   174篇
外科学   138419篇
综合类   26014篇
现状与发展   5篇
一般理论   268篇
预防医学   67751篇
眼科学   21105篇
药学   66071篇
  6篇
中国医学   2147篇
肿瘤学   46445篇
  2018年   7868篇
  2015年   8335篇
  2014年   11850篇
  2013年   17641篇
  2012年   23981篇
  2011年   25173篇
  2010年   14673篇
  2009年   13723篇
  2008年   23546篇
  2007年   25590篇
  2006年   25510篇
  2005年   25129篇
  2004年   24506篇
  2003年   23500篇
  2002年   22602篇
  2001年   36220篇
  2000年   36854篇
  1999年   31273篇
  1998年   9389篇
  1997年   8718篇
  1996年   8613篇
  1995年   8108篇
  1994年   7821篇
  1992年   26806篇
  1991年   26242篇
  1990年   25742篇
  1989年   24794篇
  1988年   23313篇
  1987年   22965篇
  1986年   21801篇
  1985年   21145篇
  1984年   16417篇
  1983年   14022篇
  1982年   8895篇
  1981年   8232篇
  1980年   7700篇
  1979年   16766篇
  1978年   12141篇
  1977年   10197篇
  1976年   9338篇
  1975年   10163篇
  1974年   12653篇
  1973年   12147篇
  1972年   11547篇
  1971年   10696篇
  1970年   10222篇
  1969年   9913篇
  1968年   8908篇
  1967年   8234篇
  1966年   7656篇
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
11.
Cutaneous leiomyomas are rare benign smooth‐muscle tumors. These lesions are distinguished based on their cell of origin and are subclassified as pilar leiomyoma, angioleiomyoma, and genital‐type leiomyoma. Nipple leiomyoma is the least common genital‐type leiomyoma, arising from the dartoic muscle cell of the nipple. Histologic examination of the lesion is necessary for definitive diagnosis, and these uncommon tumors can pose a diagnostic challenge. We describe herein a series of six nipple leiomyomas with a spectrum of histologic appearances.  相似文献   
12.
13.
14.
Objective: Human epidermal growth factor receptor 2 (erbb2/HER2) overexpression, has now been implicatedin advanced gastric and gastroesophageal junction cancers. The study was conducted to determine the rate of HER2positivity in patients with locally advanced or metastatic gastric and gastroesophageal adenocarcinoma in North-EastIndia and to assess the impact of various demographic and clinical parameters on HER2 positivity. Methods: A total of68 patients of age >18 years of gastric and gastroesophageal adenocarcinoma diagnosed on histopathological examinationfrom September 2016 to February 2018 at Dr B Borooah Cancer Institute, Assam were enrolled for the observational(epidemiological) study. All patients were subjected to the HER2 immunohistochemistry test using a FDA-approved,standardized test kit. HER2 expression was correlated with various demographic and clinicopathological parameters.Results: The overall rate of HER2 positivity in the population studied was 56% (n=38). The rate was non-significantlyhigher in male, older age group (>60 years) and Hindu population. Similarly, HER2 positivity rate was higher in patientswith well differentiated histology and was more common in patients with stage II and III diseases, but neither of theassociations is statistically significant. HER2 positivity rate was significantly higher in proximal and in GEJ tumours(56% versus 44%, P=0.002). Conclusion: HER2 overexpression was evident in 56% of the North-East Indian patientswith locally advanced and metastatic gastric and gastroesophageal adenocarcinoma. The overexpression correlatedsignificantly with primary tumour site. Routine testing of gastric and gastroesophageal tumours for HER2 expressionis recommended to provide a therapeutic advantage in Indian patients.  相似文献   
15.

Objective

Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.

Methods

Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.

Results

In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.

Conclusions

Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection.  相似文献   
16.
17.
18.
19.
20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号